COVID19 Clinical Trial
— DYNAMICOfficial title:
Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study
Verified date | April 2022 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of reducing or even abolishing the cytokine explosion and thus the evolution towards a serious form of the disease which can lead to death. Three criteria support the rational use of tetrcycline in COVI-19 (1) The coronaviruses is known to bind to metalloproteases (MMPs) of the host, in particular to ensure viral survival. Tetracyclines are known to chelate zinc from MMPs. Their chelating activity may help inhibit COVID19 infection by limiting its ability to replicate in the host. (2) Tetracyclines may also be able to inhibit the replication of positive-polarity single-stranded RNA viruses, such as COVID19 (demonstrated on the dengue virus). (3) In addition, tetracyclines are modulators of innate immunity (anti-inflammatory activity), a property used in the treatment of inflammatory skin diseases for many years. These modulating effects are noted on several targets of innate immunity: They can decrease the expression of NFKB, the release of inflammatory cytokines such as TNF-α, IL-1β and IL-6, inhibit granulomas inflammatory and free radical release. Tetracyclines could therefore participate in limiting the cytokine release induced by COVID19. Their lipophilic nature and their strong pulmonary penetration could allow them to inhibit viral replication.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 1, 2021 |
Est. primary completion date | February 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 46 Years and older |
Eligibility | Inclusion Criteria: - Man or woman > 45 years old. - Patient with a positive SARS-CoV-2 PCR - Patient with ENT and / or respiratory symptoms, without hospitalization criteria (no dyspnea, respiratory rate <22 / min, SaO2 = 94% in ambient air), or digestive signs. - Patient with at least one of the following risk factors for unfavorable outcome: - 70 years, BMI> 30, cardiovascular history (stroke, coronary artery disease, complicated hypertension, cardiac surgery, NYHA III or IV heart failure), respiratory pathology likely to decompensate during viral infection respiratory failure, unbalanced and / or complicated diabètes, respiratory pathology likely to decompensate in the event of of viral infection, patients with renal insufficiency chronic dialysis, .cancer patients under treatment. Exclusion Criteria: - Lactose-intolerant patients - Patient needing immediate hospitalization for any medical reason - Patient having more than 5 days of clinical symptoms at the inclusion visit - Patients with a history of allergy to tetracyclines - Pregnant or lactating women - Patients participating in another clinical trial - Patients with photosensitive skin pathology - Patients treated with anticoagulant - Patients treated with oral retinoids: isotretinoin, alitretinoin, acitretin - Patients treated with vitamin A Patients treated with systemic antibiotics for the duration of treatment - Patients treated with barbiturates, carbamazepine or phenytoin - Patients with treatment that may have an effect on COVID-19 infection: chloroquine, hydroxychloroquine, remdesivir, ganciclovir, acyclovir, ribavirin, lopinavir-ritonavir - Patients under guardianship or trusteeship or in safeguard of justice |
Country | Name | City | State |
---|---|---|---|
France | CHU Avicenne - APHP | Bobigny | |
France | CHU Bordeaux | Bordeaux | |
France | CHU Caen | Caen | |
France | CHU Dijon | Dijon | |
France | CHU Grenoble | Grenoble | |
France | CHU Nantes | Nantes |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Patients with Clinical Respiratory Aggravation | Percentage of patients with clinical worsening (SaO2 = 93%) after at least 48 hours of treatment | after at least 48 hours of treatment | |
Primary | Percentage of patients hospitalized | Percentage of patients hospitalized after at least 48 hours of experimental treatment | after at least 48 hours of experimental treatment | |
Primary | Percentage of patients requiring ventilatory assistance | Percentage of patients requiring ventilatory assistance | Day 0 to Day 28 | |
Secondary | Positive SARS-CoV-2 PCR Test | Number of positive SARS-CoV-2 PCR tests on D-1 / D0 and D7 (+/- 2 days) | Day -1 or day 0 AND Day 7 | |
Secondary | Duration of symptoms | Duration of symptoms (fever, painful symptoms: headache, sore throat, dyspnea) | Day 0 to Day 28 | |
Secondary | Duration of hospitalization | Total duration of hospitalization | From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0 | |
Secondary | Hospitalization intensive care or reanimation | Duration of hospitalization in intensive care or reanimation | From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0 | |
Secondary | Duration of mechanical ventilatory assistance | Duration of mechanical ventilatory assistance | to the end of mechanical ventilatory assistance if any, assessed up to 3 months after Day0 | |
Secondary | Percentage of deaths related to SARS-CoV-2 | Percentage of deaths related to SARS-CoV-2 infection | Day 28, or end of hospitalization if any (assessed up to 3 months after Day0) | |
Secondary | AE / SAE in both arms | Number of AE / SAE in both arms | Day 28, or end of hospitalization if any (assessed up to 3 months after Day0) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |